MainboardGMP
LIVE
LIVE GMP
Shellz India Ltd₹0·Tonbo Imaging India Ltd₹+498·Zetwerk Manufacturing Business Ltd₹+22·Bonfiglioli Transmissions Ltd₹+160·Sahajanand Medical Technologies Ltd₹+46·Ravita Engineering Services Ltd₹+4·Fusion CX Ltd₹+17·Jio Platforms Ltd₹+222·HD Fire Protect Ltd₹+80·Vaibhav Vyapaar Ltd₹0·R.K.Fashion Accessories Ltd₹0·Vishal Nirmiti Ltd₹+8·Nityas Gems & Jewellery Ltd₹+1·Paramount Syntex Ltd₹0·Acme India Industries Ltd₹+47·TNA Solutions Ltd₹+10·Dove Soft Ltd₹0·Omara Ventures India Ltd₹0·Shellz India Ltd₹0·Tonbo Imaging India Ltd₹+498·Zetwerk Manufacturing Business Ltd₹+22·Bonfiglioli Transmissions Ltd₹+160·Sahajanand Medical Technologies Ltd₹+46·Ravita Engineering Services Ltd₹+4·Fusion CX Ltd₹+17·Jio Platforms Ltd₹+222·HD Fire Protect Ltd₹+80·Vaibhav Vyapaar Ltd₹0·R.K.Fashion Accessories Ltd₹0·Vishal Nirmiti Ltd₹+8·Nityas Gems & Jewellery Ltd₹+1·Paramount Syntex Ltd₹0·Acme India Industries Ltd₹+47·TNA Solutions Ltd₹+10·Dove Soft Ltd₹0·Omara Ventures India Ltd₹0·
Home › IPOs › Sahajanand Medical Technologies Ltd
SA
Sahajanand Medical Technologies Ltd
● OPEN NSE & BSE Bookbuilding IPO OFS only Sahajanand Medical Technologies IPO GMP
GREY MARKET PREMIUM
₹ + 46
+13% expected return
EST. LISTING PRICE
₹390
Issue Price: ₹ 344
Issue Price
₹344
Face Value
₹1
Lot Size
43 shares
IPO Size
Agg. upto ₹475 Cr
Open Date
15 Oct 2026
Close Date
19 Oct 2026
Allotment
21 Oct 2026
Listing Date
23 Oct 2026
Exchange
NSE & BSE
Sahajanand Medical Technologies IPO About the Company

Incorporated in October 2001, Sahajanand Medical Technologies Limited is a medical technology company engaged in the development, manufacturing and marketing of technologically advanced medical devices, primarily focused on vascular intervention and structural heart intervention. Its product portfolio includes coronary stents, coronary balloons, transcatheter aortic valve implantation (TAVI) devices, occluders, renal stents and peripheral drug-coated balloons (DCBs). The Company focuses on research and development, precision manufacturing and clinically supported product innovation. Its flagship brands include Supraflex Cruz, Cocoon and Hydra, serving different areas of interventional cardiology.

The Company operates three manufacturing facilities, two in India and one in Thailand, supported by two R&D centres in India and Thailand. As of June 30, 2026, it had 119 patents granted globally, 78 patent applications in the pipeline and five design registrations in India. Its products were marketed in 77 countries in Fiscal 2026, through direct, hybrid and distributor-led models, with established market presence in India, Europe and other international markets.

The Company reported revenue from operations of ₹12,105.04 million in Fiscal 2026, compared with ₹10,248.79 million in Fiscal 2025 and ₹9,016.04 million in Fiscal 2024.

As of June 30, 2026, it had 1,605 full-time employees, 31 consultants and 707 contract-based employees. 

Competitive Strengths

  • Extensive global sales and marketing network.
  • Strong research and development capabilities.
  • Diversified and integrated manufacturing facilities.
  • Leadership in India and key international markets.
  • Proven M&A and strategic collaboration capabilities.
  • Technologically advanced medical devices in high-barrier segments.
  • Experienced leadership team backed by reputed institutional investors.
...read more
Sahajanand Medical Technologies IPO Objects of the Issue
Purpose Amount (₹ Cr)
—
Sahajanand Medical Technologies IPO Lead Managers
Motilal Oswal Investment Advisors Ltd Avendus Capital Pvt.Ltd HSBC Securities & Capital Markets (India) Pvt.Ltd. Nuvama Wealth Management Ltd
Financial Summary Amount in ₹ Crore
Metric 30 Jun 2026 31 Mar 2026 31 Mar 2025
Total Assets 1,309 1,276 1,095
Revenue 354 1,219 1,036
PAT 15 69 25
EBITDA 49 171 128
Net Worth 632 616 545
Reserves 707 692 581
Total Borrowing 321 270 225
Sahajanand Medical Technologies IPO Key Financial Ratios
ROE
2
ROCE
3
RONW
2
PAT Margin
4
EBITDA Margin
14
Debt/Equity
0
Issue Details
Total Shares Offered
9,750,482
Pre-Issue Shareholding
101,646,778 shares
Post-Issue Shareholding
101,646,778 shares
IPO Size
Agg. upto ₹475 Cr
IPO Analytics Dashboard
LIVE
Sahajanand Medical Technologies IPO GMP Insights
📊
Valuation
Weak
Sahajanand Medical Technologies IPO GMP Strength Score
2 / 10 Weak
0–3 Weak 3–6 Moderate 6–8 Good 8–10 Strong
Sahajanand Medical Technologies IPO Category-wise Subscription Shares offered, bid & amount
Category Sub (x) Offered Bid For
🏦 QIB 0.37 2,714,424 1,009,726
💼 NII / HNI 0.20 2,035,817 415,896
👤 Retail (RII) 0.41 4,750,241 1,923,906
Σ Total 0.35 9,750,482 3,370,211

* Amount calculated at upper price band (₹344) ·  ** Total includes all investor categories

Sahajanand Medical Technologies IPO Application Sizing Minimum investment by category
👤 Retail Investors ?
Min. Lots 1
Shares / Lot 43
Min. Investment 14,792
💼 HNI Investors ?
Min. Lots 14
Min. Shares 602
Min. Investment 207,088
🏛️ bHNI (>₹10L) ?
Min. Lots 68
Min. Shares 2,924
Min. Investment 1,005,856
Sahajanand Medical Technologies IPO Valuation — EPS & P/E Pre & post-issue metrics
Pre-Issue EPS ?
₹ 7
Post-Issue EPS ?
₹ 6
Pre-Issue P/E ?
51 x
Post-Issue P/E ?
58 x
Sahajanand Medical Technologies IPO Timeline & Key Dates
  1. 1 💳 Initiation of Refund 22 Oct 2026
  2. 2 📂 Credit of Shares to Demat 22 Oct 2026
Investor Interpretation
  • The IPO P/E of 58x reflects a weak valuation relative to typical market ranges.
  • Pre-issue EPS of ₹7 compares to post-issue EPS of ₹6 after dilution.

This IPO has relatively lower interest or stretched valuation. Proceed with thorough research and caution.

Sahajanand Medical Technologies IPO Company Info
📍 Sahajanand Estate, Wakharia Wadi, NR. Dabholi Char Rasta Nani Ved, Ved Road Surat, Gujarat, 395004
Visit Website
Sahajanand Medical Technologies IPO Registrar
MUFG Intime India Pvt.Ltd
Check Allotment Status
Sahajanand Medical Technologies IPO FAQs
The latest GMP of Sahajanand Medical Technologies IPO is ₹46 (+13% of issue price), which points to an estimated listing price of around ₹390. GMP is an unofficial grey-market indicator and can change anytime — it is not a guarantee of listing gains.
The issue price of Sahajanand Medical Technologies IPO is ₹344 per share. One lot has 43 shares, so the minimum investment is about ₹14,792. The total IPO size is up to ₹475 Cr. It is a OFS only issue.
Sahajanand Medical Technologies IPO opened on 15 Oct 2026 and closes on 19 Oct 2026. Allotment is tentatively expected on 21 Oct 2026. Shares are proposed to be listed on NSE & BSE on 23 Oct 2026.
Incorporated in October 2001, Sahajanand Medical Technologies Limited is a medical technology company engaged in the development, manufacturing and marketing of technologically advanced medical devices, primarily focused on vascular intervention and structural heart intervention.
The lead managers of Sahajanand Medical Technologies IPO are Motilal Oswal Investment Advisors Ltd, Avendus Capital Pvt.Ltd, HSBC Securities & Capital Markets (India) Pvt.Ltd., Nuvama Wealth Management Ltd.
Sahajanand Medical Technologies IPO is proposed to list on NSE & BSE; it is a Bookbuilding IPO and the issue is a OFS only.
Disclaimer

The information on mainboardgmp.com is provided for educational and informational purposes only.

We are not a Securities and Exchange Board of India (SEBI)-registered investment advisor, analyst, broker, or financial planner. The content, data, and insights on this website, including Grey Market Premium (GMP), subscription data, IPO dates, and market information, are not intended as financial advice or recommendations to buy, sell, or hold securities.

GMP and related IPO data are collected from unofficial market sources and may not reflect actual IPO listing performance or future price movements. You should not rely solely on the information provided here to make financial or investment decisions.

Investing in IPOs and securities involves risk. Always conduct your own research and consult a qualified SEBI-registered financial advisor before making investment decisions. mainboardgmp.com and its owners shall not be liable for any financial losses, trading losses, or damages arising from use of this website.

By using this website, you acknowledge and agree that you use the content at your own risk.